RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
  CAD
  CHF
  Clinical Trials
  Hypertension
  Myocardial Infarction
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
CHF Channel

subscribe to CHF newsletter
Latest Research : Cardiology : CHF

   EMAIL   |   PRINT
Extended Phase II Results of Furosemide GR(TM) in Congestive Heart Failure

Jun 4, 2005 - 11:45:00 AM
"While Furosemide GR tablets resulted in comparable total fluid output compared to immediate release furosemide, we are disappointed that the data didn't show a consistent improvement in urinary urgency and frequency as was observed in our Phase I trial in healthy volunteers."

 
[RxPG] Depomed, Inc. (Nasdaq:DEPO) today announced results from its extended Phase II trial of Furosemide GR(TM), a controlled release formulation of the leading diuretic furosemide, which is used to treat edema in congestive heart failure (CHF) patients. Additional data from ten patients who underwent additional treatment indicated that Furosemide GR continued to produce comparable diuresis to immediate release furosemide, however with variable urinary urgency and frequency between the two treatment groups.

"While Furosemide GR tablets resulted in comparable total fluid output compared to immediate release furosemide, we are disappointed that the data didn't show a consistent improvement in urinary urgency and frequency as was observed in our Phase I trial in healthy volunteers," said John W. Fara, Ph.D., chairman, president and chief executive officer of Depomed. "Even though the extended study involved follow up in only ten patients from the initial Phase II trial, we believe the data warrant a re-evaluation of our pursuing a diuretic program in this patient population."

The company indicated that while it is re-evaluating the program, resources that were dedicated to Furosemide GR development will be reallocated to grow its pipeline with new programs as well as support its other late stage programs, including two products, Glumetza(TM) and Proquin(TM) XR, both under review at the FDA, and another product, Gabapentin GR(TM), currently in Phase II clinical testing. The company may choose to conduct additional development of Furosemide GR in a different patient population at a later time.

In September 2004, the company reported results from a Phase II clinical trial which involved 30 CHF patients to compare Furosemide GR to immediate release furosemide. The data showed comparable diuresis between the two treatment groups, but inconsistent results related to urinary urgency and frequency. The extended Phase II program was designed to evaluate potential differentiation of Depomed's controlled release product compared to the immediate release product, particularly related to urinary frequency and urgency.

Furosemide is a diuretic used to treat edema, a swelling due to excess fluid that is often associated with congestive heart failure, kidney diseases and liver diseases. Immediate release formulations of furosemide often result in an intense peak removal of fluid from the body, which Depomed has characterized as the "Niagara effect," that may lead to poor patient compliance. Depomed's Furosemide GR is a once daily, controlled release formulation of furosemide intended to achieve a moderated and gradual diuretic effect.



Publication: Depomed
On the web: www.depomedinc.com 

Advertise in this space for $10 per month. Contact us today.


Related CHF News
T-tubule disruption occurs before decline in heart function detectable
New technology to identify compounds that triggers heart failure
Arousal disorder in patients with cardiac failure?
Exercise improves life for heart failure patients
Gene therapy trial for advanced heart failure promising
Longer anthracycline therapy reduces heart failure in adult cancer patients
Seven-point system gauges seriousness of heart failure in elderly
Famotidine may help to slow progression of chronic heart failure
Ilk gene underlies heart failure
Nocturnal Hypertension Increase Congestive Heart Failure Risk

Subscribe to CHF Newsletter

Enter your email address:


 Additional information about the news article
About Depomed

Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative Gastric Retention (GR(TM)) system to develop novel oral products and improved, extended release formulations of existing oral drugs. GR-based products are designed to provide once daily administration and reduced gastrointestinal side effects, improving patient convenience, compliance and pharmacokinetic profiles. Regulatory applications for once daily Glumetza(TM) (Metformin GR) for the treatment of Type II diabetes have been submitted to agencies in the U.S. and Canada. Depomed has been notified that the NDA for Glumetza is approvable. In addition, an NDA has been submitted to the FDA for once daily Proquin(TM) (ciprofloxacin HCl extended-release tablets) for the treatment of urinary tract infections. The company is also conducting a Phase II trial with the pain drug Gabapentin GR. Additional information about Depomed may be found at its web site, www.depomedinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the Company's Securities and Exchange Commission filings, including the Company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contacts

Depomed, Inc.
Sylvia Wheeler, 650-462-5900
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)